Silexion Therapeutics Files Proxy Materials
Ticker: SLXNW · Form: DEFA14A · Filed: Aug 12, 2025 · CIK: 2022416
Sentiment: neutral
Topics: proxy-filing, corporate-actions, name-change
TL;DR
Silexion (fka Biomotion) filed proxy docs 8/12, no fee. Watch for shareholder votes.
AI Summary
Silexion Therapeutics Corp. filed a Definitive Additional Materials proxy statement on August 12, 2025. The company, formerly known as Biomotion Sciences until May 6, 2024, is involved in the biological products sector. The filing is related to the 1934 Securities Exchange Act and does not require a filing fee.
Why It Matters
This filing indicates ongoing corporate actions and communications with shareholders, which can impact investor decisions and the company's strategic direction.
Risk Assessment
Risk Level: low — This is a routine proxy filing and does not contain information suggesting immediate or significant risk.
Key Players & Entities
- Silexion Therapeutics Corp (company) — Registrant
- Biomotion Sciences (company) — Former company name
- August 12, 2025 (date) — Filing date
- May 6, 2024 (date) — Date of name change
FAQ
What is the purpose of this DEFA14A filing?
This filing is a Definitive Additional Materials proxy statement filed by Silexion Therapeutics Corp. under the Securities Exchange Act of 1934.
When was this filing submitted?
The filing was submitted on August 12, 2025.
Has Silexion Therapeutics Corp. always been known by this name?
No, the company was formerly known as Biomotion Sciences until a name change on May 6, 2024.
Is there a fee associated with this filing?
No, the filing indicates that no fee is required.
What industry is Silexion Therapeutics Corp. in?
Silexion Therapeutics Corp. is in the Biological Products (No Diagnostic Substances) industry, SIC code 2836.
Filing Stats: 1,346 words · 5 min read · ~4 pages · Grade level 14.8 · Accepted 2025-08-12 10:31:44
Key Financial Figures
- $20,000 — mpany's authorized share capital from US$20,000 divided into 1,481,482 ordinary shares
- $0.0135 — 482 ordinary shares of a par value of US$0.0135 each, to US$121,500 divided into 9,000,
- $121,500 — of a par value of US$0.0135 each, to US$121,500 divided into 9,000,000 ordinary shares
- $2.5 million — ch requires that Silexion have at least $2.5 million of shareholders' equity on a continued
Filing Documents
- zk2533623.htm (DEFA14A) — 22KB
- image0.jpg (GRAPHIC) — 377KB
- 0001178913-25-002799.txt ( ) — 542KB
Forward-Looking Statements
Forward-Looking Statements This announcement contains forward-looking statements within the meaning of the federal securities laws. All statements other than "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them, or similar terminology. Forward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ materially from those projected or implied by those statements. Important factors that could cause such differences include, but are not limited to: (i) Silexion's strategy, future operations, financial position, projected costs, prospects, and plans; (ii) the impact of the regulatory environment and compliance complexities; (iii) Silexion's future capital requirements and sources and uses of cash, including its ability to obtain additional capital; (iv) Silexion's ability to maintain its Nasdaq listing and restore compliance with all Nasdaq Listing Rules; and (v) other risks and uncertainties set forth in the documents filed or to be filed with the SEC by the Company, including the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 18, 2025 (the " 2024 Annual Report "). Silexion cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking statement is made. Forward-looking statements set forth herein spea